Core Insights - The 17th China Bio-Industry Conference opened on September 4, focusing on "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World" with an emphasis on "high-end, professional, international, and market-oriented" approaches [1] Group 1: Event Overview - The conference showcased numerous well-known companies presenting cutting-edge technologies, products, and applications, highlighting the latest advancements in the global bio-industry [1] Group 2: Exhibitor Highlights - BGI Genomics displayed tissue slices applied in spatiotemporal chips [3] - The Optics Brain-Computer Interface and near-infrared brain function imaging device from the Optics Valley Biocity exhibition area attracted significant attention from foreign guests [4] - United Imaging Healthcare presented a 5T magnetic resonance imaging system [6] - Heyuan Bio showcased recombinant human albumin injection (from rice) [7]

Core Insights - The establishment of the brain-computer interface (BCI) outpatient clinic at Huazhong University of Science and Technology's Tongji Hospital marks a significant advancement in the application of neuroscience and artificial intelligence in medical treatment in Hubei province [1][6] Group 1: Patient Experience - The first patient, Ms. Xia, successfully underwent non-invasive brain signal collection, expressing confidence in her future rehabilitation [1][2] - Ms. Xia suffered from left-side paralysis due to a brain hemorrhage and sought better treatment options after limited success with various therapies [2][4] Group 2: Clinical Procedures - The outpatient clinic employs both invasive and non-invasive BCI methods, with a team of neurologists and neurosurgeons assessing patients to determine the most suitable treatment [4][10] - Ms. Xia underwent a series of evaluations, including a behavioral assessment where she scored 13 out of 57, indicating moderate paralysis [4][5] Group 3: Technology and Methodology - The BCI clinic utilizes a dual-signal collection system, combining 32-channel electrical signals and a 90-channel near-infrared signal system, improving accuracy to 75% [5] - The brain signal collection process took approximately 30 minutes, with data analyzed through artificial intelligence algorithms and manual review [5][10] Group 4: Future Developments - The hospital plans to conduct clinical trials for semi-invasive BCI procedures, targeting conditions such as spinal cord injuries and aiming to enhance patient functionality through thought-controlled movements [6][10] - The BCI outpatient clinic will provide nationwide access to BCI technology assessments and treatment consultations, establishing a long-term follow-up database to support ongoing technology optimization [10]

智通财经APP获悉，据报道，苹果公司(AAPL.US)正试图整合一项技术，使人类能够使用神经信号来控 制他们的iPhone。媒体称，苹果公司与初创公司Synchron合作研发新型脑机接口，以帮助残疾人使用其 设备。 麦肯锡预计，2030年至2040年，全球脑机接口在医疗领域应用的潜在市场规模有望从400亿美元增至 1450亿美元。 太平洋证券认为，利好政策为脑机接口技术的临床应用提供了保障，促进了高水平医疗创新技术的成果 转化和临床应用。中信证券此前指出，脑机接口是新质生产力最具潜力的发展方向之一，国内外脑机企 业都在积极推动脑机接口在医疗、工业、娱乐等多领域商业化。 脑机接口相关概念港股： 南京熊猫电子股份(00553)：由南京熊猫规划科技部牵头组织申报的"基于脑机接口技术的多模态人机交 互系统集成关键技术研发"此前成功入选2022年江苏省重点研发计划产业前瞻与关键核心技术项目。 微创脑科学(02172)：公司是神经介入领域领军企业，产品和技术优势显著，有望充分享受行业快速发 展和进口替代红利， 目前已实现盈利，业绩端有望保持快速增长趋势。宣布其全资附属公司微创神通 医疗科技（上海）与多个投资方于2024年 ...

Group 1: Brain-Computer Interface (BCI) Development - The Chinese Academy of Sciences has developed a flexible microelectrode implantation robot named CyberSense, which can precisely implant flexible electrodes into animal brains, supporting BCI and neuroscience research [1] - CyberSense has successfully supported various specifications of flexible microelectrodes developed by other research institutes, indicating a collaborative effort in advancing BCI technology [1] - The upcoming International Forum on Neurotechnology in Shanghai will focus on cutting-edge technologies in neural regulation, including adaptive brain stimulation techniques for treating complex brain diseases [1] Group 2: Market and Regulatory Developments - Hubei Province has set government-guided prices for invasive and non-invasive BCI procedures, with the highest limits being 6552 yuan for implantation and 966 yuan for non-invasive adaptation, reflecting a structured approach to BCI pricing in China [2] - By early 2025, most BCI products approved by the regulatory authority are expected to be non-invasive, with a projected market size of 2.63 billion yuan and a market share of 82% for non-invasive interfaces by 2024 [2] - The BCI sector is recognized as a significant area for new productive forces, with companies actively pursuing commercialization across various fields such as healthcare, industry, and entertainment [2] Group 3: Company Insights - Nanjing Panda Electronics has successfully been selected for a key R&D project focused on multi-modal human-computer interaction systems based on BCI technology, indicating its commitment to innovation in this field [3] - Micron Medical Science, a leader in neuro-intervention, is expected to benefit from rapid industry growth and import substitution, with a promising growth trend in its performance [3] - Micron Medical Science has established a private equity investment fund with a total capital commitment of 1 billion yuan, indicating strong financial backing for future developments in brain science and artificial intelligence [3]